{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:19:32Z","timestamp":1790867972413,"version":"4.1.0"},"reference-count":130,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["148361"],"award-info":[{"award-number":["148361"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.antiviral.2019.01.011","type":"journal-article","created":{"date-parts":[[2019,1,26]],"date-time":"2019-01-26T16:24:30Z","timestamp":1548519870000},"page":"91-105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":99,"special_numbering":"C","title":["Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance"],"prefix":"10.1016","volume":"163","author":[{"given":"Jocelyne","family":"Piret","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Boivin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2019.01.011_bib1","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.transproceed.2013.01.082","article-title":"Maribavir use in practice for cytomegalovirus infection in French transplantation centers","volume":"45","author":"Alain","year":"2013","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.antiviral.2019.01.011_bib2","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2174\/187152609787847758","article-title":"Drug targets in cytomegalovirus infection","volume":"9","author":"Andrei","year":"2009","journal-title":"Infect. Disord. - Drug Targets"},{"key":"10.1016\/j.antiviral.2019.01.011_bib3","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1399-3062.2010.00550.x","article-title":"Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients","volume":"12","author":"Avery","year":"2010","journal-title":"Transpl. Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.01.011_bib4","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1099\/vir.0.022293-0","article-title":"Modification of the major tegument protein pp65 of human cytomegalovirus inhibits virus growth and leads to the enhancement of a protein complex with pUL69 and pUL97 in infected cells","volume":"91","author":"Becke","year":"2010","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2019.01.011_bib5","doi-asserted-by":"crossref","first-page":"7393","DOI":"10.1128\/JVI.02825-12","article-title":"Human cytomegalovirus pUL97 regulates the viral major immediate early promoter by phosphorylation-mediated disruption of histone deacetylase 1 binding","volume":"87","author":"Bigley","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.01.011_bib6","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1073\/pnas.82.8.2473","article-title":"Metabolic activation of the nucleoside analog 9-[(2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine in human diploid fibroblasts infected with human cytomegalovirus","volume":"82","author":"Biron","year":"1985","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2019.01.011_bib7","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1128\/AAC.46.8.2365-2372.2002","article-title":"Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action","volume":"46","author":"Biron","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.01.011_bib8","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1128\/JVI.72.3.2259-2264.1998","article-title":"The gene product of human cytomegalovirus open reading frame UL56 binds the pac motif and has specific nuclease activity","volume":"72","author":"Bogner","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.01.011_bib9","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1128\/JVI.01967-07","article-title":"The essential human cytomegalovirus gene UL52 is required for cleavage-packaging of the viral genome","volume":"82","author":"Borst","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.01.011_bib10","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1128\/JVI.01955-12","article-title":"The human cytomegalovirus UL51 protein is essential for viral genome cleavage-packaging and interacts with the terminase subunits pUL56 and pUL89","volume":"87","author":"Borst","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.01.011_bib11","doi-asserted-by":"crossref","first-page":"5860","DOI":"10.1128\/JVI.00384-16","article-title":"The essential human cytomegalovirus proteins pUL77 and pUL93 are structural components necessary for viral genome encapsidation","volume":"90","author":"Borst","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.01.011_bib12","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.antiviral.2018.09.003","article-title":"New therapies for human cytomegalovirus infections","volume":"159","author":"Britt","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.01.011_bib13","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/rmv.1873","article-title":"Human cytomegalovirus antiviral drug resistance in hematopoietic stem cell transplantation: current state of the art","volume":"26","author":"Campos","year":"2016","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.antiviral.2019.01.011_bib14","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/135965350701200209","article-title":"New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc","volume":"12","author":"Champier","year":"2007","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2019.01.011_bib15","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1177\/135965350801300504","article-title":"Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity","volume":"13","author":"Champier","year":"2008","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2019.01.011_bib16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/15257770008032999","article-title":"Synthesis and evaluation of a series of 2'-deoxy analogues of the antiviral agent 5,6-dichloro-2-isopropylamino-1-(beta-L-ribofuranosyl)-1H-benzimidazole (1263W94)","volume":"19","author":"Chan","year":"2000","journal-title":"Nucleos Nucleot. Nucleic Acids"},{"key":"10.1016\/j.antiviral.2019.01.011_bib17","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1309533","article-title":"Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation","volume":"370","author":"Chemaly","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2019.01.011_bib18","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1111\/ajt.15135","article-title":"Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection","volume":"18","author":"Cherrier","year":"2018","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.antiviral.2019.01.011_bib19","doi-asserted-by":"crossref","DOI":"10.1111\/tid.12965","article-title":"Letermovir successfully used for secondary prophylaxis in a heart transplant recipient with ganciclovir-resistant cytomegalovirus syndrome (UL97 mutation)","volume":"20","author":"Chong","year":"2018","journal-title":"Transpl. Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.01.011_bib20","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1128\/AAC.01177-08","article-title":"Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir","volume":"53","author":"Chou","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.01.011_bib21","doi-asserted-by":"crossref","first-page":"6588","DOI":"10.1128\/AAC.01623-15","article-title":"Rapid in vitro evolution of human cytomegalovirus UL56 mutations that confer letermovir resistance","volume":"59","author":"Chou","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.01.011_bib22","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01325-17","article-title":"Comparison of cytomegalovirus terminase gene mutations selected after exposure to three distinct inhibitor compounds","volume":"61","author":"Chou","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.01.011_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2017.10.019","article-title":"A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance","volume":"148","author":"Chou","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.01.011_bib24","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1128\/AAC.00577-06","article-title":"Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus","volume":"50","author":"Chou","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.01.011_bib25","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1128\/JVI.01787-07","article-title":"Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant","volume":"82","author":"Chou","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.01.011_bib26","doi-asserted-by":"crossref","first-page":"7124","DOI":"10.1128\/JVI.78.13.7124-7130.2004","article-title":"Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir","volume":"78","author":"Chou","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.01.011_bib27","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1128\/AAC.49.7.2710-2715.2005","article-title":"Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene","volume":"49","author":"Chou","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.01.011_bib28","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1128\/AAC.00736-07","article-title":"Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens","volume":"51","author":"Chou","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.01.011_bib29","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1086\/518514","article-title":"Cytomegalovirus UL97 kinase mutations that confer maribavir resistance","volume":"196","author":"Chou","year":"2007","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.01.011_bib30","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.antiviral.2012.05.013","article-title":"Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo","volume":"95","author":"Chou","year":"2012","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.01.011_bib31","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1128\/AAC.05559-11","article-title":"Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure","volume":"56","author":"Chou","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.01.011_bib32","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1128\/AAC.00511-13","article-title":"Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance","volume":"57","author":"Chou","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.01.011_bib33","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.antiviral.2018.07.013","article-title":"Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus","volume":"157","author":"Chou","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.01.011_bib34","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00922-18","article-title":"A new locus of drug resistance in the human cytomegalovirus UL56 gene revealed by in vitro exposure to letermovir and ganciclovir","volume":"62","author":"Chou","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.01.011_bib35","doi-asserted-by":"crossref","first-page":"104","DOI":"10.2165\/00003495-199141010-00009","article-title":"Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis","volume":"41","author":"Chrisp","year":"1991","journal-title":"Drugs"},{"key":"10.1016\/j.antiviral.2019.01.011_bib36","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0026-895X(25)09608-7","article-title":"Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells","volume":"50","author":"Cihlar","year":"1996","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.antiviral.2019.01.011_bib37","doi-asserted-by":"crossref","first-page":"14660","DOI":"10.1128\/JVI.79.23.14660-14667.2005","article-title":"Interaction of the putative human cytomegalovirus portal protein pUL104 with the large terminase subunit pUL56 and its inhibition by benzimidazole-D-ribonucleosides","volume":"79","author":"Dittmer","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.01.011_bib38","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jcv.2006.07.010","article-title":"Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet","volume":"37","author":"Drew","year":"2006","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.antiviral.2019.01.011_bib39","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1128\/JCM.01275-13","article-title":"Novel method based on \"en passant\" mutagenesis coupled with a Gaussia luciferase reporter assay for studying the combined effects of human cytomegalovirus mutations","volume":"51","author":"Drouot","year":"2013","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.antiviral.2019.01.011_bib40","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1128\/JCM.02205-14","article-title":"Characterization of multiple cytomegalovirus drug resistance mutations detected in a hematopoietic stem cell transplant recipient by recombinant phenotyping","volume":"52","author":"Drouot","year":"2014","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.antiviral.2019.01.011_bib41","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3851\/IMP3028","article-title":"Artesunate demonstrates in vitro synergism with several antiviral agents against human cytomegalovirus","volume":"21","author":"Drouot","year":"2016","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2019.01.011_bib42","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1182\/blood.V96.9.3286","article-title":"Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes","volume":"96","author":"Eckle","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.antiviral.2019.01.011_bib43","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/cts.12483","article-title":"Intravenous hydroxypropyl beta-cyclodextrin formulation of letermovir: a phase I, randomized, single-ascending, and multiple-dose trial","volume":"10","author":"Erb-Zohar","year":"2017","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.antiviral.2019.01.011_bib44","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1128\/AAC.48.10.3918-3927.2004","article-title":"Inhibition of human cytomegalovirus replication by benzimidazole nucleosides involves three distinct mechanisms","volume":"48","author":"Evers","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.01.011_bib45","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/j.bbmt.2018.05.017","article-title":"Comparative efficacy and safety of different antiviral agents for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis","volume":"24","author":"Gagelmann","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.antiviral.2019.01.011_bib46","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.antiviral.2018.11.005","article-title":"Targeting the terminase: an important step forward in the treatment and prophylaxis of human cytomegalovirus infections","volume":"161","author":"Gentry","year":"2019","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.01.011_bib47","doi-asserted-by":"crossref","first-page":"10884","DOI":"10.1128\/JVI.05265-11","article-title":"The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase","volume":"85","author":"Goldner","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.01.011_bib48","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1128\/AAC.01794-13","article-title":"Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure","volume":"58","author":"Goldner","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.01.011_bib49","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1128\/AAC.00951-07","article-title":"Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults","volume":"52","author":"Goldwater","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.01.011_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000275","article-title":"Viral mimicry of Cdc2\/cyclin-dependent kinase 1 mediates disruption of nuclear lamina during human cytomegalovirus nuclear egress","volume":"5","author":"Hamirally","year":"2009","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2019.01.011_bib51","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1126\/science.3291115","article-title":"The protein kinase family: conserved features and deduced phylogeny of the catalytic domains","volume":"241","author":"Hanks","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2019.01.011_bib52","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1177\/135965350901400510","article-title":"Conserved domains and structure prediction of human cytomegalovirus UL27 protein","volume":"14","author":"Hantz","year":"2009","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2019.01.011_bib53","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1128\/jvi.71.1.405-411.1997","article-title":"The human cytomegalovirus UL97 protein is a protein kinase that autophosphorylates on serines and threonines","volume":"71","author":"He","year":"1997","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.01.011_bib54","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.3390\/v2102213","article-title":"Synthesis and early development of hexadecyloxypropylcidofovir: an oral antipoxvirus nucleoside phosphonate","volume":"2","author":"Hostetler","year":"2010","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2019.01.011_bib55","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.3389\/fmicb.2016.01317","article-title":"Detection of low frequency multi-drug resistance and novel putative maribavir resistance in immunocompromised pediatric patients with cytomegalovirus","volume":"7","author":"Houldcroft","year":"2016","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.antiviral.2019.01.011_bib56","doi-asserted-by":"crossref","first-page":"6943","DOI":"10.1074\/jbc.M108984200","article-title":"ATPase activity of the terminase subunit pUL56 of human cytomegalovirus","volume":"277","author":"Hwang","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2019.01.011_bib57","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1128\/AAC.00571-11","article-title":"Cyclopropavir inhibits the normal function of the human cytomegalovirus UL97 kinase","volume":"55","author":"James","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.01.011_bib58","doi-asserted-by":"crossref","first-page":"10659","DOI":"10.1128\/JVI.00497-07","article-title":"Human cytomegalovirus protein kinase UL97 forms a complex with the tegument phosphoprotein pp65","volume":"81","author":"Kamil","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.01.011_bib59","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.chom.2011.02.001","article-title":"HATs on for drug resistance","volume":"9","author":"Kamil","year":"2011","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.antiviral.2019.01.011_bib60","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1600-6143.2011.03530.x","article-title":"First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246","volume":"11","author":"Kaul","year":"2011","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.antiviral.2019.01.011_bib61","article-title":"Breakthrough cytomegalovirus pneumonia in hematopoietic stem cell transplant recipient on letermovir prophylaxis","author":"Knoll","year":"2018","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.antiviral.2019.01.011_bib62","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1081\/NCN-120023123","article-title":"Resistance of human cytomegalovirus to D- and L-ribosyl benzimidazoles as a tool to identify potential targets for antiviral drugs","volume":"22","author":"Komazin","year":"2003","journal-title":"Nucleos Nucleot. Nucleic Acids"},{"key":"10.1016\/j.antiviral.2019.01.011_bib63","doi-asserted-by":"crossref","first-page":"11499","DOI":"10.1128\/JVI.77.21.11499-11506.2003","article-title":"Resistance of human cytomegalovirus to the benzimidazole L-ribonucleoside maribavir maps to UL27","volume":"77","author":"Komazin","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.01.011_bib64","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1128\/AAC.01726-13","article-title":"Human cytomegalovirus UL97 kinase is involved in the mechanism of action of methylenecyclopropane analogs with 6-ether and -thioether substitutions","volume":"58","author":"Komazin-Meredith","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.01.011_bib65","doi-asserted-by":"crossref","first-page":"5876","DOI":"10.1128\/JVI.00351-16","article-title":"Intracellular distribution of capsid-associated pUL77 of human cytomegalovirus and interactions with packaging proteins and pUL93","volume":"90","author":"Koppen-Rung","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.01.011_bib66","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1128\/AAC.46.8.2373-2380.2002","article-title":"Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication","volume":"46","author":"Koszalka","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.01.011_bib67","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.antiviral.2019.01.011_bib68","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1111\/bcp.13376","article-title":"Pharmacokinetics and safety of the anti-human cytomegalovirus drug letermovir in subjects with hepatic impairment","volume":"83","author":"Kropeit","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.antiviral.2019.01.011_bib69","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1111\/bcp.13292","article-title":"Pharmacokinetics and safety of letermovir, a novel anti-human cytomegalovirus drug, in patients with renal impairment","volume":"83","author":"Kropeit","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.antiviral.2019.01.011_bib70","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/cpdd.388","article-title":"Pharmacokinetics and safety of letermovir coadministered with cyclosporine A or tacrolimus in healthy subjects","volume":"7","author":"Kropeit","year":"2018","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.antiviral.2019.01.011_bib71","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1128\/JVI.77.2.905-914.2003","article-title":"The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress","volume":"77","author":"Krosky","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.01.011_bib72","doi-asserted-by":"crossref","first-page":"7720","DOI":"10.1128\/JVI.77.14.7720-7727.2003","article-title":"The human cytomegalovirus UL44 protein is a substrate for the UL97 protein kinase","volume":"77","author":"Krosky","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.01.011_bib73","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1128\/AAC.46.9.2969-2976.2002","article-title":"Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding","volume":"46","author":"Lalezari","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.01.011_bib74","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/femsre\/fuy004","article-title":"The human cytomegalovirus terminase complex as an antiviral target: a close-up view","volume":"42","author":"Ligat","year":"2018","journal-title":"FEMS Microbiol. Rev."},{"key":"10.1016\/j.antiviral.2019.01.011_bib75","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1128\/AAC.01596-09","article-title":"In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246","volume":"54","author":"Lischka","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.01.011_bib76","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/infdis\/jiv352","article-title":"Characterization of cytomegalovirus breakthrough events in a phase 2 prophylaxis trial of letermovir (AIC246, MK 8228)","volume":"213","author":"Lischka","year":"2016","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.01.011_bib77","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1128\/CMR.00009-10","article-title":"Antiviral drug resistance of human cytomegalovirus","volume":"23","author":"Lurain","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.antiviral.2019.01.011_bib78","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1128\/AAC.50.4.1130-1135.2006","article-title":"Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults","volume":"50","author":"Ma","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2019.01.011_bib79","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1093\/ofid\/ofw172.1834","article-title":"Maribavir versus valganciclovir for preemptive treatment of cytomegalovirus (CMV) viremia: a randomized, dose-ranging, phase 2 study among hematopoietic stem cell transplant (SCT) and solid organ transplant (SOT) recipients","volume":"3","author":"Maertens","year":"2016","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.01.011_bib80","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jcv.2006.11.005","article-title":"Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients","volume":"38","author":"Marfori","year":"2007","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.antiviral.2019.01.011_bib81","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1099\/0022-1317-82-6-1439","article-title":"Inhibitors of human cytomegalovirus replication drastically reduce the activity of the viral protein kinase pUL97","volume":"82","author":"Marschall","year":"2001","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2019.01.011_bib82","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0042-6822(03)00147-8","article-title":"The protein kinase pUL97 of human cytomegalovirus interacts with and phosphorylates the DNA polymerase processivity factor pUL44","volume":"311","author":"Marschall","year":"2003","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2019.01.011_bib83","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1128\/AAC.05908-11","article-title":"In vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (letermovir) against herpesviruses and other human pathogenic viruses","volume":"56","author":"Marschall","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.01.011_bib84","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/jcph.1094","article-title":"Pharmacokinetics and tolerability of letermovir coadministered with azole antifungals (posaconazole or voriconazole) in healthy subjects","volume":"58","author":"Marshall","year":"2018","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.antiviral.2019.01.011_bib85","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jcv.2010.08.008","article-title":"Contrasting effects on ganciclovir susceptibility and replicative capacity of two mutations at codon 466 of the human cytomegalovirus UL97 gene","volume":"49","author":"Martin","year":"2010","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.antiviral.2019.01.011_bib86","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jcv.2010.01.009","article-title":"Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis","volume":"47","author":"Martin","year":"2010","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.antiviral.2019.01.011_bib87","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.coviro.2011.10.011","article-title":"Maribavir and human cytomegalovirus-what happened in the clinical trials and why might the drug have failed?","volume":"1","author":"Marty","year":"2011","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.antiviral.2019.01.011_bib88","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1473-3099(11)70024-X","article-title":"Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial","volume":"11","author":"Marty","year":"2011","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.01.011_bib89","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa1303688","article-title":"CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation","volume":"369","author":"Marty","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2019.01.011_bib90","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2019.01.011_bib91","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.bbmt.2018.09.038","article-title":"A randomized, double-blind, placebo-controlled phase 3 trial of oral brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic-cell transplantation","volume":"25","author":"Marty","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.antiviral.2019.01.011_bib92","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1128\/AAC.45.10.2925-2927.2001","article-title":"Susceptibilities of human cytomegalovirus clinical isolates to BAY38-4766, BAY43-9695, and ganciclovir","volume":"45","author":"McSharry","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.01.011_bib93","series-title":"PREVYMIS: Package Insert and Label Information","author":"Merck Sharp & Dohme Corp","year":"2017"},{"key":"10.1016\/j.antiviral.2019.01.011_bib94","doi-asserted-by":"crossref","first-page":"6340","DOI":"10.1128\/jvi.70.9.6340-6346.1996","article-title":"The UL97 gene product of human cytomegalovirus is an early-late protein with a nuclear localization but is not a nucleoside kinase","volume":"70","author":"Michel","year":"1996","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.01.011_bib95","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1093\/nar\/gkf524","article-title":"Sequence analysis of bacteriophage T4 DNA packaging\/terminase genes 16 and 17 reveals a common ATPase center in the large subunit of viral terminases","volume":"30","author":"Mitchell","year":"2002","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.antiviral.2019.01.011_bib96","series-title":"39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco","article-title":"Safety, tolerability and pharmacokinetics of single oral doses of BAY 38-4766\u2013a novel, non-nucleosidic inhibitor of human cytomegalovirus replication\u2013in healthy male subjects","author":"Nagelschmitz","year":"1999"},{"key":"10.1016\/j.antiviral.2019.01.011_bib97","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02384-16","article-title":"Mutual interplay between the human cytomegalovirus terminase subunits pUL51, pUL56, and pUL89 promotes terminase complex formation","volume":"91","author":"Neuber","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.01.011_bib98","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.antiviral.2018.08.015","article-title":"In vitro evaluation of current and novel antivirals in combination against human cytomegalovirus","volume":"158","author":"O'Brien","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.01.011_bib99","article-title":"Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: a randomized, dose-ranging, double-blind, phase 2 study","author":"Papanicolaou","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.01.011_bib100","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1128\/AAC.44.10.2811-2815.2000","article-title":"Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients","volume":"44","author":"Pescovitz","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.01.011_bib101","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1111\/j.1600-6143.2009.02768.x","article-title":"A randomized, double-blind, pharmacokinetic study of oral maribavir with tacrolimus in stable renal transplant recipients","volume":"9","author":"Pescovitz","year":"2009","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.antiviral.2019.01.011_bib102","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.antiviral.2014.08.014","article-title":"Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism","volume":"111","author":"Pilorge","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.01.011_bib103","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01044-17","article-title":"Drug susceptibility and replicative capacity of multidrug-resistant recombinant human cytomegalovirus harboring mutations in UL56 and UL54 genes","volume":"61","author":"Piret","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.01.011_bib104","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/rmv.615","article-title":"Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir","volume":"19","author":"Prichard","year":"2009","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.antiviral.2019.01.011_bib105","doi-asserted-by":"crossref","first-page":"5663","DOI":"10.1128\/JVI.73.7.5663-5670.1999","article-title":"A recombinant human cytomegalovirus with a large deletion in UL97 has a severe replication deficiency","volume":"73","author":"Prichard","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.01.011_bib106","doi-asserted-by":"crossref","first-page":"15494","DOI":"10.1128\/JVI.79.24.15494-15502.2005","article-title":"Human cytomegalovirus UL97 Kinase is required for the normal intranuclear distribution of pp65 and virion morphogenesis","volume":"79","author":"Prichard","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.01.011_bib107","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1743-422X-3-18","article-title":"Human cytomegalovirus UL27 is not required for viral replication in human tissue implanted in SCID mice","volume":"3","author":"Prichard","year":"2006","journal-title":"Virol. J."},{"key":"10.1016\/j.antiviral.2019.01.011_bib108","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/jac\/48.6.757","article-title":"Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38-4766): in vitro and in vivo antiviral activity and mechanism of action","volume":"48","author":"Reefschlaeger","year":"2001","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2019.01.011_bib109","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1128\/JVI.00007-13","article-title":"Inactivation of retinoblastoma protein does not overcome the requirement for human cytomegalovirus UL97 in lamina disruption and nuclear egress","volume":"87","author":"Reim","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.01.011_bib110","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.chom.2011.01.006","article-title":"Antiviral inhibition targeting the HCMV kinase pUL97 requires pUL27-dependent degradation of Tip60 acetyltransferase and cell-cycle arrest","volume":"9","author":"Reitsma","year":"2011","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.antiviral.2019.01.011_bib111","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1093\/nar\/30.7.1695","article-title":"The terminase subunits pUL56 and pUL89 of human cytomegalovirus are DNA-metabolizing proteins with toroidal structure","volume":"30","author":"Scheffczik","year":"2002","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.antiviral.2019.01.011_bib112","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1093\/nar\/gkg229","article-title":"Identification of the ATP-binding site in the terminase subunit pUL56 of human cytomegalovirus","volume":"31","author":"Scholz","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.antiviral.2019.01.011_bib113","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2042-4280-1-4","article-title":"The effects of maribavir on the autophosphorylation of ganciclovir resistant mutants of the cytomegalovirus UL97 protein","volume":"1","author":"Shannon-Lowe","year":"2010","journal-title":"Herpesviridae"},{"key":"10.1016\/j.antiviral.2019.01.011_bib114","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1128\/JVI.02426-14","article-title":"Human cytomegalovirus UL97 phosphorylates the viral nuclear egress complex","volume":"89","author":"Sharma","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.01.011_bib115","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/tri.12225","article-title":"Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study","volume":"27","author":"Stoelben","year":"2014","journal-title":"Transpl. Int."},{"key":"10.1016\/j.antiviral.2019.01.011_bib116","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1086\/653122","article-title":"Virologic characterization of multidrug-resistant cytomegalovirus infection in 2 transplant recipients treated with maribavir","volume":"202","author":"Strasfeld","year":"2010","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.01.011_bib117","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/0091270006296765","article-title":"Pharmacokinetics of maribavir, a novel oral anticytomegalovirus agent, in subjects with varying degrees of renal impairment","volume":"47","author":"Swan","year":"2007","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.antiviral.2019.01.011_bib118","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1099\/vir.0.005827-0","article-title":"Cytomegaloviral protein kinase pUL97 interacts with the nuclear mRNA export factor pUL69 to modulate its intranuclear localization and activity","volume":"90","author":"Thomas","year":"2009","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2019.01.011_bib119","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2018.01.003","article-title":"Thymidine kinase and protein kinase in drug-resistant herpesviruses: heads of a lernaean hydra","volume":"37","author":"Topalis","year":"2018","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.antiviral.2019.01.011_bib120","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02337-18","article-title":"Use of letermovir as salvage therapy for drug-resistant CMV retinitis: a case series","author":"Turner","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.01.011_bib121","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1128\/JVI.72.1.717-725.1998","article-title":"Inhibition of human cytomegalovirus DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 gene product","volume":"72","author":"Underwood","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.01.011_bib122","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1128\/AAC.48.5.1647-1651.2004","article-title":"Mechanism of action of the ribopyranoside benzimidazole GW275175X against human cytomegalovirus","volume":"48","author":"Underwood","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.01.011_bib123","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1128\/AAC.47.4.1334-1342.2003","article-title":"Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects","volume":"47","author":"Wang","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.01.011_bib124","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1128\/AAC.00114-15","article-title":"In vitro drug combination studies of Letermovir (AIC246, MK-8228) with approved anti-human cytomegalovirus (HCMV) and anti-HIV compounds in inhibition of HCMV and HIV replication","volume":"59","author":"Wildum","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.01.011_bib125","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1128\/AAC.47.7.2186-2192.2003","article-title":"In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses","volume":"47","author":"Williams","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.01.011_bib126","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.1182\/blood-2007-11-121558","article-title":"Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study","volume":"111","author":"Winston","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.antiviral.2019.01.011_bib127","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1111\/j.1600-6143.2012.04231.x","article-title":"Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial","volume":"12","author":"Winston","year":"2012","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.antiviral.2019.01.011_bib128","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/0006-2952(96)00100-1","article-title":"Kinetic analysis of the interaction of cidofovir diphosphate with human cytomegalovirus DNA polymerase","volume":"51","author":"Xiong","year":"1996","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.antiviral.2019.01.011_bib129","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/ki.2013.399","article-title":"Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport","volume":"85","author":"Yeung","year":"2014","journal-title":"Kidney Int."},{"key":"10.1016\/j.antiviral.2019.01.011_bib130","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.virusres.2017.01.019","article-title":"Herpesvirus DNA polymerases: structures, functions and inhibitors","volume":"234","author":"Zarrouk","year":"2017","journal-title":"Virus Res."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218307009?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218307009?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:29:18Z","timestamp":1759062558000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354218307009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":130,"alternative-id":["S0166354218307009"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.01.011","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}